Poland· PL-100479299
Pyrukynd
A mitapivat product containing mitapivatum, registered in Poland by Agios Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mitapivat is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AX04 (mitapivat), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Mitapivat · ATC B06AX04
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Mitapivatum
- Manufacturer
- Agios Netherlands B.V.
- Country
- Poland (PL)
- ATC code
- B06AX04
- ATC class
- Mitapivat
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin03400930267653
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mitapivat in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesPYRUKYNDAgios Pharmaceuticals, Inc.
- SpainPYRUKYND 50 MG + 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAgios Netherlands B.V.
- SwedenPyrukynd 50 mg + 20 mg Filmdragerad tablettAgios Netherlands B.V.
- BelgiumPyrukynd 50 mgAgios Netherlands
- IcelandPyrukyndAgios Netherlands B.V.
- NetherlandsPyrukynd 50 mg, filmomhulde tablettenAgios Netherlands B.V.
- IrelandPyrukynd 50 mg film-coated tabletsAgios Netherlands B.V.
- CzechiaPYRUKYNDAgios Netherlands B.V., Amsterdam
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pyrukynd
- Liechtenstein · Pyrukynd
- Norway · Pyrukynd
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df0015e3-53c0-42c0-99a8-77c0c36310a0 GET /v1/drugs/df0015e3-53c0-42c0-99a8-77c0c36310a0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg",
"packaging": "Rp ¦ EU/1/22/1662/006 ¦ 148745\n56 tabl.\n¦ UR/Z/4b/080/26 - 03400930267653 ¦ UR/Z/4b/240/26 - 03400930267653",
"substance": "Mitapivati sulfas 50 mg",
"common_name": "Mitapivatum",
"pl_product_id": "100479299",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about mitapivat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.